Acta Oncologica最新文献

{"title":"How does pulmonary function impact QoL in patients with locally advanced NSCLC treated with chemoradiotherapy and durvalumab?","authors":"Frigg Å Sommervoll, Henrik Horndalsveen, Dag Einar Sommervoll, Jussi Koivonen, Tarje Onsøien Halvorsen, Bjørn Henning Grønberg, Marianne Aanerud, Saulius Cicenas, Nina Helbekkmo, Jarkko Ahvonen, Maria Silvoniemi, Gina Barrera, Maria M Bjaanæs, Vilde Haakensen, Åsa Öjlert, Kersti Oselin, Åslaug Helland, Tesfaye Madebo","doi":"10.2340/1651-226X.2026.45040","DOIUrl":"10.2340/1651-226X.2026.45040","url":null,"abstract":"<p><strong>Background: </strong>Impaired pulmonary function is common among patients with lung cancer and may negatively affect health-related quality of life (HRQoL). The primary objective of the present sub-study of the DART-trial was to assess the overall quality of life changes during treatment and stratified by the presence of Chronic Obstructive Pulmonary Disease (COPD).</p><p><strong>Methods: </strong>The investigator-initiated DART trial (NCT04392505) included patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with chemoradiotherapy followed by durvalumab. Baseline pulmonary function was measured by spirometry, and patients were stratified by FEV1/FVC <70% (COPD) or ≥70% (non-COPD). HRQoL was assessed regularly using the EORTC QLQ-C30 and QLQ-LC13 questionnaires at screening and during treatment. A difference in mean score of ≥10 was defined as clinically significant.</p><p><strong>Results: </strong>A total of 86 patients initiated durvalumab and completed at least one HRQoL assessment; pulmonary function data were available for 64 patients. For the overall cohort, quality of life scores remained stable throughout treatment. Patients with COPD consistently reported lower global health scores than those with preserved lung function. The global health score among patients with COPD was not significantly different at end of treatment compared to baseline, however significantly lower than patients without COPD. Symptom trajectories across QLQ-C30 scales were stable in both groups. Dyspnoea was more prevalent among patients with COPD. In the LC13 module, no clinically significant differences were observed except for dyspnoea, which was consistently higher among patients with COPD.</p><p><strong>Interpretation: </strong>The HRQoL remained stable during chemoradiotherapy and durvalumab treatment in stage III NSCLC patients. Impaired lung function was associated with modestly lower HRQoL, though larger studies are needed to confirm subgroup effects.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"232-240"},"PeriodicalIF":2.7,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13006962/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility of lung cancer screening in low-risk populations of the Nordic countries.","authors":"Mef Nilbert, Gunnar Wagenius, Simon Ekman","doi":"10.2340/1651-226X.2026.45489","DOIUrl":"10.2340/1651-226X.2026.45489","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"228-231"},"PeriodicalIF":2.7,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005171/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147472267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The false-negative rate of sentinel lymph node biopsy and its related factors in early-stage cervical cancer: a systematic review and meta-analysis.","authors":"Chao He, Fei Li, Min He, Jia Li","doi":"10.2340/1651-226X.2026.44984","DOIUrl":"10.2340/1651-226X.2026.44984","url":null,"abstract":"<p><strong>Background and purpose: </strong>The objective of this systematic review and meta-analysis was to evaluate the false-negative rate (FNR) of sentinel lymph node biopsy (SLNB) performed in patients with early-stage cervical cancer (ECC), and to study the risk factors affecting FNR.</p><p><strong>Material and methods: </strong>We searched three databases (Embase, MEDLINE, and Cochrane Central Library) for articles published in the last decade from January 2014 to September 2024. Publications on patients with ECC who underwent SLNB, with information on the FNR of SLNB, were included. The QUADAS-2 tool was used to assess the risk of bias and the clinical applicability of the included studies. The FNR and associated factors were synthesized using random-effects meta-analysis and meta-regression.</p><p><strong>Results: </strong>A total of 49 eligible studies with a low to moderate risk of bias were included in the final analysis. The overall FNR was 10.9% (95 CI: 6.0-16.7). No significant differences in FNR were found for different reference standards or tumor diameters (< 2 cm vs. ≥ 2 cm). However, different tracers (e.g. methylene blue [MB], carbon nanoparticle [CNP], indocyanine green [ICG], and Technetium-99m [Tc-99m] combined with other tracers) appear to account for the different FNRs. In the meta-regression analysis, we found that the proportion of SLNs located in the obturator area was significantly negatively associated with FNR (coefficient = -0.88, p = 0.04).</p><p><strong>Interpretation: </strong>The overall FNR of SLNB for ECC was approximately 10.9%. Factors that tended to reduce the FNR included using a low-volume metastatic detection technique, having a tumor diameter of < 2 cm, employing specific tracer regimens, and identifying more than one lymph node in the obturator fossa.</p><p><strong>Registration: </strong>PROSPERO (CRD42024608411).</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"213-227"},"PeriodicalIF":2.7,"publicationDate":"2026-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001021/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world management of patients with simultaneously diagnosed synchronous liver and lung metastatic colorectal cancer - a national cohort study.","authors":"Laia Faseh, Petter Fruhling, Helena Taflin, Jenny Lundmark Rystedt, Caroline Williamsson, Oskar Hemmingsson, Bergthor Björnsson, Marco Gerling, Ernesto Sparrelid, Per Sandström, Kristina Hasselgren, Jennie Engstrand","doi":"10.2340/1651-226X.2026.45045","DOIUrl":"10.2340/1651-226X.2026.45045","url":null,"abstract":"<p><strong>Background and purpose: </strong>Real-world data on management and outcomes of patients with simultaneously diagnosed synchronous colorectal liver and lung metastases are limited. This national study evaluated referral patterns, treatment strategies, and survival in a population-based cohort. Patient/material and methods: This retrospective cohort study used Swedish national registries to identify patients with synchronous liver and lung metastatic colorectal cancer (CRC), defined as metastases detected within 6 months of CRC diagnosis between 2008 and 2016. Medical record review provided additional information on diagnosis confirmation, multidisciplinary team (MDT) referral, metastatic burden, and treatment. Logistic regression identified factors associated with MDT referral and curative treatment, and Cox regression with a time-varying covariate assessed survival.</p><p><strong>Results: </strong>Among 2703 registry-identified patients, medical records were accessible for 855. After exclusion of extrahepatic, non-pulmonary metastases, 556 remained for analysis. A total of 189 patients (34%) were discussed at a liver MDT conference. Referred patients were younger, had lower metastatic burden, and better performance status than non-referred. Median survival was 24 months (95% CI [confidence interval] 21-28) for referred versus 10 months (95% CI 7-12) for non-referred patients. Curative local treatment of liver and/or lung metastases was performed in 101 patients (18%), and complete metastasectomy in 34 (6%), conferring superior survival compared with liver-only intervention (hazard ratio 0.34, 95% CI 0.18-0.61). The main reason for non-referral was presumed non-resectability.</p><p><strong>Interpretation: </strong>Referral to an MDT and subsequent local treatment were associated with improved survival, although this may partly reflect favorable patient and tumor characteristics influencing referral and treatment decisions. Patients with adequate physiological reserve should routinely be evaluated in an organ-specific MDT for potential curative treatment.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"201-212"},"PeriodicalIF":2.7,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12993435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147429803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study.","authors":"Anton Barchuk, Cesar Barboza, Julieta Politi, Berta Raventós, Peter Prinsen, Jelle Evers, Vincent Ky Ho, Michiel Aj Van de Sande, Eric Fey, Kimmo Porkka, Anna Hammais, Tiina Wahlfors, Tuomo Nieminen, Toni Lehtonen, Antonella Delmestri, Guillaume Verdy, Romain Griffier, Airam De Burgos-González, Ana Llorente-Garcia, Cristina Justo-Astorgano, Miguel-Angel Macia-Martinez, Olli Tenhunen, Anja Schiel, Alexandra Pacurariu, Ross Brennan, Ross Williams, Katia Verhamme, Talita Duarte Salles","doi":"10.2340/1651-226X.2026.45117","DOIUrl":"10.2340/1651-226X.2026.45117","url":null,"abstract":"<p><strong>Background and purpose: </strong>Chondrosarcoma is a rare bone malignancy with a poor response to systemic therapy in advanced stages. European-level epidemiological data remain scarce. This study aimed to characterise patient demographics, treatments and survival using real-world data to inform regulatory decisions about the feasibility and design of new trials for the systemic treatment of chondrosarcoma. Patient/material and methods: This cohort study, part of the DARWIN EU® initiative, analysed data from six healthcare databases in Finland, France, the Netherlands, Spain and the UK. Patients diagnosed with chondrosarcoma between 2010 and 2022 were identified. Standardised analyses were performed within a federated network using the Observational Medical Outcomes Partnership (OMOP) Common Data Model.</p><p><strong>Results: </strong>A total of 2,498 chondrosarcoma patient records were identified, covering at least 2,356 unique patients. Median age at diagnosis was 52-55 years, with a balanced sex distribution. Surgical treatment was the most common intervention, recorded in 15.2% to 88.9% of patients, depending on the database. Fewer than 5% received systemic anticancer therapy, and radiotherapy was reported in fewer than 7%. The 10-year overall survival (OS) ranged from 58% (95% confidence interval [CI]: 43-78) to 80% (95% CI: 78-82), with restricted mean survival between 7.4 and 8.7 years. In the Netherlands, patients with late-stage, metastatic or high-grade disease showed significantly poorer outcomes.</p><p><strong>Interpretation: </strong>This study demonstrates the feasibility of using real-world data across Europe to describe chondrosarcoma patients. Most had early-stage, low-grade disease amenable to surgery, with limited use of systemic therapies. Survival was generally favourable, except in advanced disease. Clinical trials remain difficult due to the rarity of advanced chondrosarcoma and the lack of standards.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"193-200"},"PeriodicalIF":2.7,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12988406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147429772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of dumping after oesophageal cancer surgery.","authors":"Pernilla Lagergren, Laima Kampa, Kalle Mälberg, William Jebril, Johan Hardvik Åkerström, Asif Johar, Anna Schandl","doi":"10.2340/1651-226X.2026.45044","DOIUrl":"10.2340/1651-226X.2026.45044","url":null,"abstract":"<p><strong>Introduction: </strong>Dumping syndrome is a common consequence following oesophagectomy and may lead to reduced food intake, resulting in subsequent weight loss, and negatively impact health-related quality of life. This study aimed to develop a predictive model to facilitate preventive treatment planning by identifying individuals at an increased risk of developing dumping syndrome.</p><p><strong>Materials and methods: </strong>Data were obtained from a nationwide, population-based cohort of patients who underwent oesophagectomy for cancer between 2013 and 2020. Patient and clinical characteristics were retrieved from national health registries and medical records. Dumping symptoms were self-reported 1 year after surgery. Multivariable regression models provided odds ratios (OR) with 95% confidence intervals (CI). Model performance was evaluated using the area under the receiver operating characteristic curve (AUC).</p><p><strong>Results: </strong>Among the 384 individuals, 41 (11%) developed significant symptoms of dumping. The following variables that increased the probability of developing dumping were included in the final prediction model: younger age, female sex, higher preoperative body mass index, no neoadjuvant therapy, Charlson Comorbidity Index score > 0, open oesophagectomy, cervical anastomosis, and less severe postoperative complications (lower Clavien Dindo grade). For the prediction of early dumping symptoms, the AUC for the total cohort was 0.74 (95% CI: 0.64-0.83) and after cross-validation, 0.62 (95% CI: 0.53-0.72). For early and late symptoms, the AUC was 0.75 (95% CI: 0.67-0.83), and for the cross-validated model, 0.65 (95% CI: 0.56-0.74).</p><p><strong>Interpretation: </strong>This study offers insights into factors associated with dumping syndrome after oesophagectomy. The prediction model showed modest ability to distinguish between high and low-risk patients, and should therefore be interpreted as supportive rather than definitive. Its potential value lies in complementing clinical judgement, informing structured follow-up and guiding future research.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"186-192"},"PeriodicalIF":2.7,"publicationDate":"2026-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12973169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147363859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Merging clinical research and standard healthcare - Nordic Precision Cancer Medicine Symposium 2025.","authors":"Elisa Bjørgo, Nina Ånensen, Gro Live Fagereng, Hege G Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland","doi":"10.2340/1651-226X.2026.45168","DOIUrl":"10.2340/1651-226X.2026.45168","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"181-185"},"PeriodicalIF":2.7,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in tumor mutational burden assessment: a national ring trial.","authors":"Christine Federspiel Secher, Christina Westmose Yde, Britt Elmedal Laursen, Estrid Høgdall, Henriette Sylvain Thomsen, Tim Svenstrup Poulsen, Mads Sønderkær, Tina Kringelbach, Mads Malik Aagaard Jørgensen, Rikke Frydendahl Sick Olsen, Anja Elaine Sørensen, Christian Baudet, Magnús Halldór Gíslason, Michael Knudsen, Ida Kappel Buhl","doi":"10.2340/1651-226X.2026.45220","DOIUrl":"10.2340/1651-226X.2026.45220","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"178-180"},"PeriodicalIF":2.7,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12966816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147353420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specialized healthcare diagnostic events within one year preceding colorectal cancer diagnosis.","authors":"Elina Hermiö, Salla E Toikkanen, Liisa H Pylkkänen, Jutta Järvelin, Janne M Pitkäniemi, Nea K Malila, Karri J Seppä","doi":"10.2340/1651-226X.2026.44788","DOIUrl":"10.2340/1651-226X.2026.44788","url":null,"abstract":"","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"173-177"},"PeriodicalIF":2.7,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12961377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Stockholm Pilot study for Lung cancer Screening (Stockholm PLUS): feasibility of baseline low-dose CT lung cancer screening in a high-risk Swedish female population.","authors":"Oscar Grundberg, Paulina Kalinowska, Pierre Hillegren, Nicolas Peyrard Janvid, Axel Dimberg, Nina Markholm Nordgren, Fredrik Strand, Vitali Grozman, Gunnar Wagenius","doi":"10.2340/1651-226X.2026.44826","DOIUrl":"10.2340/1651-226X.2026.44826","url":null,"abstract":"<p><strong>Background and purpose: </strong>Low-dose CT screening of high-risk groups has been shown to reduce lung cancer mortality, and the European Council has therefore recommended that member states explore the feasibility and effectiveness of this approach. In this study, we evaluate the implementation of low-dose CT screening for lung cancer in a Swedish female population. Patient/material and methods: Women aged 54-74 years in the Southern Stockholm region were contacted via an electronic questionnaire. Individuals who met the same eligibility criteria as in the NELSON trial (a minimum smoking history of 15 pack-years) were invited. The screening consisted of a baseline low-dose computed tomography (LDCT) scan, with the option for a follow-up scan in cases with intermediate findings. Findings were managed in accordance with modified Fleischner Society guidelines.</p><p><strong>Results: </strong>Between September 2022 and September 2024, 34,580 invitation letters were sent to randomly selected women aged 54-74 years 11,607 individuals (33.4%) completed the questionnaire, whereof 1,106 (10%) met the inclusion criteria. 990 (90%) individuals accepted the invitation and underwent a baseline low-dose CT scan. There were 152 intermediate and 55 positive scans at baseline, and additional eight positive scans at follow-up. Fifteen cases of Lung cancer were found, yielding a positive prediction value (PPV) of 24%. 87% of the lung cancers were in stage IA.</p><p><strong>Interpretation: </strong>Organized lung cancer screening in a Swedish female population proved feasible, demonstrating a good participation rate, and a cancer detection rate consistent with findings from other major screening trials.</p>","PeriodicalId":7110,"journal":{"name":"Acta Oncologica","volume":"65 ","pages":"164-172"},"PeriodicalIF":2.7,"publicationDate":"2026-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12946860/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147281730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}